quavonlimab
Term · Oncology and biomedicine · MLC-T-ONC-016321
A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, quavonlimab targets and binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.
| Identifier | MLC-T-ONC-016321 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-CTLA-4 monoclonal antibody MK-1308 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016321",
"term": "quavonlimab",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, quavonlimab targets and binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.",
"synonyms": [
"anti-CTLA-4 monoclonal antibody MK-1308"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/quavonlimab/"
}
Record 13,938 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.